Compugen Ltd (CGEN.OQ)
CGEN.OQ on NASDAQ Stock Exchange Global Market
3.75USD
18 Jun 2018
3.75USD
18 Jun 2018
Change (% chg)
-- (--)
-- (--)
Prev Close
$3.75
$3.75
Open
--
--
Day's High
--
--
Day's Low
--
--
Volume
--
--
Avg. Vol
48,528
48,528
52-wk High
$5.00
$5.00
52-wk Low
$2.25
$2.25
Revenue & Earnings Per Share
| Revenue* | Earnings Per Share** | ||
|---|---|---|---|
| FY 2018 | Mar '18 | 10.00 | 0.002 |
| FY 2017 | Dec '17 | 0.00 | -0.182 |
| Sep '17 | 0.00 | -0.193 | |
| Jun '17 | 0.00 | -0.179 | |
| Mar '17 | 0.00 | -0.170 | |
| FY 2016 | Dec '16 | 0.05 | -0.166 |
| Sep '16 | 0.07 | -0.153 | |
| Jun '16 | 0.50 | -0.131 | |
| Mar '16 | 0.09 | -0.170 |
*Note: Units in Millions ofU.S. Dollars
**Note: Units in U.S. Dollars
Consensus Estimates Analysis
| # of Estimates | Mean | High | Low | 1 Year Ago | |
|---|---|---|---|---|---|
| SALES (in millions) | |||||
| Quarter Ending Jun-18 | 3 | 0.00 | 0.00 | 0.00 | -- |
| Quarter Ending Sep-18 | 3 | 0.00 | 0.00 | 0.00 | -- |
| Year Ending Dec-18 | 3 | 15.07 | 20.20 | 10.00 | 0.20 |
| Year Ending Dec-19 | 3 | 3.40 | 10.00 | 0.00 | 0.20 |
| Earnings (per share) | |||||
| Quarter Ending Jun-18 | 3 | -0.18 | -0.16 | -0.20 | -- |
| Quarter Ending Sep-18 | 3 | -0.19 | -0.17 | -0.21 | -- |
| Year Ending Dec-18 | 3 | -0.48 | -0.42 | -0.57 | -0.40 |
| Year Ending Dec-19 | 3 | -0.77 | -0.64 | -1.00 | -0.16 |
Sales and Profit Figures in US Dollar (USD);
Valuation Ratios
| Company | industry | sector | ||
|---|---|---|---|---|
| P/E Ratio (TTM) | -- | 241.68 | 34.14 | |
| P/E High - Last 5 Yrs. | -- | 292.11 | 47.66 | |
| P/E Low - Last 5 Yrs. | -- | 101.47 | 25.16 | |
| Beta | 0.22 | 0.73 | 0.78 | |
| Price to Sales (TTM) | 20.02 | 277.62 | 8.57 | |
| Price to Book (MRQ) | 6.33 | 23.87 | 4.34 | |
| Price to Tangible Book (MRQ) | 6.58 | 31.36 | 6.03 | |
| Price to Cash Flow (TTM) | -- | 141.06 | 22.77 | |
| % Owned Institutions | 18.24 | 10.76 | 2.40 | |
Dividends
| Company | industry | sector | ||
|---|---|---|---|---|
| Dividend Yield | -- | 0.30 | 1.68 | |
| Dividend Yield - 5 Year Avg | -- | 0.20 | 1.42 | |
| Dividend 5 Year Growth Rate | -- | 2.24 | -6.55 | |
| Payout Ratio(TTM) | -- | 42.12 | 39.30 | |
Growth Rates
| Company | industry | sector | ||
|---|---|---|---|---|
| Sales (MRQ) vs Qtr. 1 Yr. Ago | -- | 24.41 | 5.00 | |
| Sales (TTM) vs TTM 1 Yr. Ago | 1,515.51 | 137.83 | 12.49 | |
| Sales - 5 Yr. Growth Rate | -- | 30.90 | 7.91 | |
| EPS (MRQ) vs Qtr. 1 Yr. Ago | 101.17 | -77.62 | 40.62 | |
| EPS (TTM) vs TTM 1 Yr. Ago | 10.97 | -- | -- | |
| EPS - 5 Yr. Growth Rate | -- | 48.46 | 8.03 | |
| Capital Spending - 5 Yr. Growth Rate | -17.46 | 36.24 | 7.42 | |
Financial Strength
| Company | industry | sector | |
|---|---|---|---|
| Quick Ratio (MRQ) | -- | 1.67 | 2.56 |
| Current Ratio (MRQ) | 5.81 | 6.36 | 3.64 |
| LT Debt to Equity (MRQ) | 0.00 | 20.82 | 12.92 |
| Total Debt to Equity (MRQ) | 0.00 | 25.13 | 17.37 |
| Interest Coverage (TTM) | -- | -141.93 | 35.98 |
Profitability Ratios
| Company | industry | sector | ||
|---|---|---|---|---|
| Gross Margin (TTM) | 96.50 | 56.43 | 54.96 | |
| Gross Margin - 5 Yr. Avg. | 70.24 | 54.95 | 52.86 | |
| EBITD Margin (TTM) | -285.07 | -- | -- | |
| EBITD - 5 Yr. Avg | -444.22 | -171.02 | 15.70 | |
| Operating Margin (TTM) | -285.07 | -947.27 | -0.77 | |
| Operating Margin - 5 Yr. Avg. | -464.34 | -184.72 | 10.94 | |
| Pre-Tax Margin (TTM) | -282.55 | -830.61 | 1.31 | |
| Pre-Tax Margin - 5 Yr. Avg. | -434.83 | -188.11 | 11.12 | |
| Net Profit Margin (TTM) | -282.55 | -823.71 | -1.98 | |
| Net Profit Margin - 5 Yr. Avg. | -439.73 | -186.54 | 7.48 | |
| Effective Tax Rate (TTM) | -- | 15.15 | 29.95 | |
| Effective Tax Rate - 5 Yr. Avg. | -- | 19.20 | 24.12 | |
Efficiency
| Company | industry | sector | ||
|---|---|---|---|---|
| Revenue/Employee (TTM) | 99,010 | 21,782,551 | 736,570,410 | |
| Net Income/Employee (TTM) | -279,752 | -431,793 | 85,786,139 | |
| Receivable Turnover (TTM) | 1.56 | 18.21 | 6.05 | |
| Inventory Turnover (TTM) | -- | 2.86 | 3.65 | |
| Asset Turnover (TTM) | 0.19 | 0.48 | 0.88 | |
Management Effectiveness
| Company | industry | sector | ||
|---|---|---|---|---|
| Return on Assets (TTM) | -54.73 | -4.01 | 10.37 | |
| Return on Assets - 5 Yr. Avg. | -30.30 | -1.12 | 11.08 | |
| Return on Investment (TTM) | -61.10 | -5.91 | 13.17 | |
| Return on Investment - 5 Yr. Avg. | -32.90 | 1.60 | 14.39 | |
| Return on Equity (TTM) | -65.58 | -7.75 | 15.14 | |
| Return on Equity - 5 Yr. Avg. | -36.17 | -3.78 | 15.73 | |
| 1 Year | 3 Year | 5 Year | |
|---|---|---|---|
| Sales % | -100.00 | -- | -- |
| EPS (TTM) % | -16.90 | -- | -- |
| Dividend % | -- | -- | -- |
Note: Units in Millions of US Dollars
Performance for Compugen Ltd
Note:: Rank is a percentile that ranges from 0 to 99, with 99 = best.
- BRIEF-Compugen Ltd - Bayer Plans To Advance Cancer Immunotherapy Program Into First-In-Human Trials In 2018
- Deals of the day-Mergers and acquisitions
- BRIEF-Compugen Announces Exclusive License Agreement With Medimmune
- Compugen, AstraZeneca unit in cancer drug development deal
- BRIEF-Compugen Reports Q4 Loss Per Share Of $0.18
Institutional Holders
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.